BioSpace News Archive

Flexion Therapeutics, Inc. announced equity inducement grants to eight new employees consisting of 18,200 restricted stock units.

Patient enrollment and dosing in the Phase 1/2 clinical trial of BDTX-189 continue to track in line with projections at initiation of the study, with dose-escalation portion on track to complete in first half of 2021; initial Phase 1 clinical pharmacokinetic (PK), safety, and preliminary efficacy data to be presented at American Society of Clinical Oncology (ASCO) Annual Meeting

Transaction values Science 37 at an enterprise value of approximately $1.05 billion at closing Positions Science 37 with a balance sheet of up to $250 million to fund its decentralized trial technology platform, extend into new adjacencies, and power the next generation in clinical research

TACTI-003 clinical trial design enables evaluation of efti in 1st line recurrent or metastatic HNSCC patients to better understand its effect in combination with pembrolizumab

Company to host conference call and webcast at 8:30 a.m. EDT

Increasing rapid antigen testing will help identify people not showing symptoms of infection who may be carrying COVID-19 into workplaces and communities

These events will be webcast live and a replay will be available on 3M’s Investor Relations website at http://investors.3M.com.

Vuzix® Corporation (NASDAQ: VUZI), (“Vuzix” or, the “Company”), a leading supplier of Smart Glasses and Augmented Reality (AR) technology and products, today announced a further volume order of Vuzix Blade® Smart Glasses in connection with the Company’s central role supporting the NextAR surgical AR platform developed by Medacta International,

Prothena Corporation plc, a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, announced that in connection with hiring two new employees, the compensation committee of the Company’s board of directors granted the individuals hired by the Company, in the aggregate, options to purchase 155,000 ordinary shares of the Company.

Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that the Company will release its 2021 first quarter financial results on Thursday, May 13, 2021, after the close of the U.S. financial markets.